广州市拜特凇医药科技有限公司

Guangzhou Baitisong Pharmaceutical Technology is a clinical-stage biotechnology company headquartered in Guangzhou, China, specializing in the discovery of innovative small molecule drugs. The company primarily focuses on metabolic diseases, such as metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes, alongside programs in oncology and immunology. Baitisong leverages a proprietary structure-based drug design platform to develop highly potent and selective therapeutic candidates targeting G-protein coupled receptors (GPCRs). Its lead asset, BTS-101, is a GPR120 agonist designed to address the complex pathology of MASH and metabolic disorders. The firm is led by a team of scientists with extensive experience in global pharmaceutical R&D and structure-based design. Baitisong aims to bridge the gap between basic science and clinical application to provide transformative treatments for patients with significant unmet medical needs.